Insulet Announces Changes to Board of Directors with Retirements and New Appointments
ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, is proud to announce significant changes to its Board of Directors. These changes, effective January 18, reflect the company’s commitment to expert guidance and strategic leadership as it continues to revolutionize the healthcare industry.
Joining the esteemed board are Flavia Pease, Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories, and Timothy Stonesifer, Chief Financial Officer at Alcon Inc. Both industry leaders bring a wealth of experience and expertise to Insulet. Their appointments demonstrate the company’s dedication to attracting top talent and strengthening its financial management capability.
Pease’s impressive background includes extensive financial leadership experience in the life sciences industry. Her strategic vision and strong financial acumen have been instrumental in her successful tenure at Charles River Laboratories. Insulet will undoubtedly benefit from her invaluable insights and guidance.
Similarly, Stonesifer’s appointment brings significant financial expertise to the board. As the CFO of Alcon Inc., his deep knowledge of financial operations and effective leadership have helped drive the company’s success. Stonesifer’s vast experience in healthcare and financial management will greatly contribute to the strategic direction of Insulet.
In addition to these important appointments, Insulet also announced the retirement of Shacey Petrovic from the board. Petrovic’s visionary leadership and dedication to advancing insulin pump technology have been pivotal in Insulet’s growth and success. The company is grateful for her invaluable contributions and wishes her the best in her future endeavors.
These changes to Insulet’s Board of Directors come at a time when the company is experiencing fluctuations in its stock price. Currently trading on the NASDAQ, Insulet Corporation’s stock is approximately 16.6% below its 52-week average. The newly appointed directors, with their impressive track records, will play an instrumental role in steering the company back to stability and driving future growth.
With its commitment to revolutionizing healthcare through innovative insulin pump technology, Insulet Corporation continues to prioritize strategic leadership and financial expertise. The newly appointed directors, Flavia Pease and Timothy Stonesifer, bring a wealth of expertise to the table and will undoubtedly contribute to the company’s continued success. Insulet thanks Shacey Petrovic for her remarkable contributions and looks forward to a bright future under the guidance of its rejuvenated Board of Directors.
Comments